Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience

BACKGROUND: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled a...

Descripción completa

Detalles Bibliográficos
Autores principales: Licari, Amelia, Castagnoli, Riccardo, Denicolò, Chiara, Rossini, Linda, Seminara, Manuela, Sacchi, Lucia, Testa, Giorgia, De Amici, Mara, Marseglia, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684803/
https://www.ncbi.nlm.nih.gov/pubmed/29213221
http://dx.doi.org/10.2174/1573398X13666170426094536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684803/
https://www.ncbi.nlm.nih.gov/pubmed/29213221
http://dx.doi.org/10.2174/1573398X13666170426094536

Ejemplares similares